Novavax announced on Thursday the different efficacy rates of its COVID-19 vaccine in two countries over the new known variant of the virus.

(Photo : Phil Walter/Getty Images)
COVID-19 vaccines from pharmaceutical companies AstraZeneca and Novavax.

Novavax, Inc., an American vaccine development company, released a statement for the first time on Thursday that the COVID-19 vaccine has reached an 89% efficacy in battling against the virus based on the early findings from a British study.

This result is promising, however, the vaccine appears to be effective to the new mutated versions in the country of South Africa, according to a press release.

Read also: Novavax Started Late-Stage Trial of COVID-19 Vaccine in U.S.

Novavax COVID-19 vaccine in United Kingdom

The chief investigator of the UK Novavax, Prof. Paul Heath, said in a statement that the findings are enormously exciting and show that the COVID-19 vaccine is vastly effective and safe. More importantly, it works well with the UK variant that has immediately spread throughout the country.

Furthermore, Health Secretary Matt Hancock stated that the National Health Service is ready to release and give the people a shot of this vaccine as soon as it gets its approval. Secretary Hancock is delighted that the UK is leading another medical breakthrough worldwide.

He has sent his gratitude to the people behind this success, brilliant scientists and researchers, and 10,000 people who selflessly volunteered themselves in the clinical trial.

The said positive trial results encourage the country's vaccine developer to create another potent vaccine against coronavirus, and they are very optimistic on making it into reality, according to a report in Associated Press.

Read also: CDC Warns More Infectious New COVID-19 Variant Could Become Dominant Strain in March

Novavax COVID-19 vaccine in South Africa

The Novavax Covid-19 vaccine appears to have high efficacy on the variant in UK. However, findings show that the vaccine does not work well on the variant in South Africa, and its immediate spread is worrisome. The released findings is perceived as threatening news for other vaccine developers, according to CBS News.

They are in panic in determining whether existing vaccines would stay efficient in fighting against the new mutated version of virus in South Africa, and are planning new forms on the off chance that the virus can get through the insurance given by the shot.

Furthermore, Shabir Madhi the leader of South African study of the University of Witwatersrand in Johannesburg gave a statement that there seem to be no any protection from the virus have been derived.

The existence of numerous extremely contagious variants gives more complications in bringing the pandemic under control, which also drives world leaders to suspend travels to places like Britain and South Africa since these places are hotspots of new variants, called B.1.351.

And findings showed that several trial volunteers were infected with the said variant even after having COVID.

The new variants of COVID-19 was first detected in the United Kingdom and ,later on, another variant was detected in South Africa. The new variants were said to be the main reason of COVID-19 spike in the area.